Evidence map›Paper›PMID 33062157›Full record

ArticleACS medicinal chemistry letters2020

Development of a Potent Brain-Penetrant EGFR Tyrosine Kinase Inhibitor against Malignant Brain Tumors.

Jonathan E Tsang, Lorenz M Urner, Gyudong Kim, Kingsley Chow, Lynn Baufeld, Kym Faull, Timothy F Cloughesy, Peter M Clark, Michael E Jung, David A Nathanson

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. A Selection Protocol to Identify Therapeutics to Target NLRP3-Associated Sensory Hearing Loss.Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology · 2024
    Article
  9. Review
  10. Discovery of 1Pharmaceuticals (Basel, Switzerland) · 2024
    Article
  11. Chemical science · 2023
    Article
  12. Article
  13. Discovery of New Pyrrolo[2,3-Pharmaceuticals (Basel, Switzerland) · 2023
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Recent advances in drug delivery and targeting to the brain.Journal of controlled release : official journal of the Controlled Release Society · 2022
    Review
  19. Current Chemical, Biological, and Physiological Views in the Development of Successful Brain-Targeted Pharmaceutics.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Jonathan E TsangDepartments of Molecular and Medical Pharmacology, Chemistry and Biochemistry, Jane and Terry Semel Institute for Neuroscience and Human Behavior and Department of Psychiatry and Biobehavioral Sciences, Neurology, and Crump Institute for Molecular Imaging, University of California, Los Angeles, California 90095, United States.
Lorenz M UrnerDepartments of Molecular and Medical Pharmacology, Chemistry and Biochemistry, Jane and Terry Semel Institute for Neuroscience and Human Behavior and Department of Psychiatry and Biobehavioral Sciences, Neurology, and Crump Institute for Molecular Imaging, University of California, Los Angeles, California 90095, United States.
Gyudong KimDepartments of Molecular and Medical Pharmacology, Chemistry and Biochemistry, Jane and Terry Semel Institute for Neuroscience and Human Behavior and Department of Psychiatry and Biobehavioral Sciences, Neurology, and Crump Institute for Molecular Imaging, University of California, Los Angeles, California 90095, United States.
Kingsley ChowDepartments of Molecular and Medical Pharmacology, Chemistry and Biochemistry, Jane and Terry Semel Institute for Neuroscience and Human Behavior and Department of Psychiatry and Biobehavioral Sciences, Neurology, and Crump Institute for Molecular Imaging, University of California, Los Angeles, California 90095, United States.
Lynn BaufeldDepartments of Molecular and Medical Pharmacology, Chemistry and Biochemistry, Jane and Terry Semel Institute for Neuroscience and Human Behavior and Department of Psychiatry and Biobehavioral Sciences, Neurology, and Crump Institute for Molecular Imaging, University of California, Los Angeles, California 90095, United States.
Kym FaullDepartments of Molecular and Medical Pharmacology, Chemistry and Biochemistry, Jane and Terry Semel Institute for Neuroscience and Human Behavior and Department of Psychiatry and Biobehavioral Sciences, Neurology, and Crump Institute for Molecular Imaging, University of California, Los Angeles, California 90095, United States.
Timothy F CloughesyDepartments of Molecular and Medical Pharmacology, Chemistry and Biochemistry, Jane and Terry Semel Institute for Neuroscience and Human Behavior and Department of Psychiatry and Biobehavioral Sciences, Neurology, and Crump Institute for Molecular Imaging, University of California, Los Angeles, California 90095, United States.
Peter M ClarkDepartments of Molecular and Medical Pharmacology, Chemistry and Biochemistry, Jane and Terry Semel Institute for Neuroscience and Human Behavior and Department of Psychiatry and Biobehavioral Sciences, Neurology, and Crump Institute for Molecular Imaging, University of California, Los Angeles, California 90095, United States.
Michael E JungDepartments of Molecular and Medical Pharmacology, Chemistry and Biochemistry, Jane and Terry Semel Institute for Neuroscience and Human Behavior and Department of Psychiatry and Biobehavioral Sciences, Neurology, and Crump Institute for Molecular Imaging, University of California, Los Angeles, California 90095, United States.
David A NathansonDepartments of Molecular and Medical Pharmacology, Chemistry and Biochemistry, Jane and Terry Semel Institute for Neuroscience and Human Behavior and Department of Psychiatry and Biobehavioral Sciences, Neurology, and Crump Institute for Molecular Imaging, University of California, Los Angeles, California 90095, United States.
University of California, Los Angeles · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Targeting metabolic vulnerabilities in glioblastomaR01CA213133 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NATHANSON, DAVID A. · 2017 to 2021
$2.5M
NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA213133
6 · The paper itself

Abstract

The epidermal growth factor receptor (EGFR) is genetically altered in nearly 60% of glioblastoma tumors; however, tyrosine kinase inhibitors (TKIs) against EGFR have failed to show efficacy for patients with these lethal brain tumors. This failure is attributed to the inability of clinically tested EGFR TKIs to cross the blood-brain barrier (BBB) and achieve adequate pharmacological levels to inhibit various oncogenic forms of EGFR that drive glioblastoma. Through SAR analysis, we developed compound

Identifiers

PMID33062157
PMCPMC7549123
OpenAlexW3020988432

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.